Menu
← Oncology Approval Tracker
FDA DECISION ·
Ponlimsi
denosumab-adet · Teva Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Prolia biosimilar with oncology supportive-care uses to increase bone mass in men at high fracture risk on androgen deprivation for nonmetastatic prostate cancer and women at high fracture risk on adjuvant aromatase inhibitors for breast cancer.
LAMPGEN ANALYSIS
Why it matters
The labeled uses address bone loss associated with cancer treatment. This product and its uses should be kept distinct from the Xgeva-referenced formulation.
What research teams should watch
Verify the underlying cancer therapy and fracture risk, and align product selection with renal and calcium safety monitoring described in the label.
PRIMARY RECORDS